Cabaletta Bio, Inc. (CABA) Dividend History

Company News

• Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

  Cabaletta Bio announced plans to submit a Biologics License Application (BLA) for its rese-cel therapy in myositis by 2027, following recent alignment with the FDA on registrational cohorts for the RESET-Myositis trial. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation for rese-cel in myositis.

  GlobeNewswire Inc.
• Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

  Cabaletta Bio, a clinical-stage biotechnology company, announced that it will participate in a fireside chat at Guggenheim's SMID Cap Biotech Conference on February 5, 2025. The company is focused on developing curative targeted cell therapies for autoimmune diseases.

  GlobeNewswire Inc.
• US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode

  US stock futures are pointing to a higher open on Friday as investors look to end November on a positive note. Analysts suggest that December has historically been a strong month for markets, with only one instance of it being the worst month in the last 95 years.

  Benzinga

  Featured Companies: BTDR FRO QQQ RGTI SPY
• Cabaletta Bio to Participate in Upcoming Investor Conferences in September

  Cabaletta Bio, a clinical-stage biotechnology company, announced its participation in several investor conferences in September 2024, including the Morgan Stanley, Wells Fargo, H.C. Wainwright, and Cantor Fitzgerald conferences.

  GlobeNewswire Inc.
• Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

  – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –

  GlobeNewswire Inc.